Journal of affective disorders · 2011
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Levkovitz Yechiel, Alpert Jonathan E, Brintz Carrie E, Mischoulon David, Papakostas George I
Аннотация
BACKGROUND: Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosyl methionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD.
METHODS: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment.
RESULTS: There was a greater improvement in the ability to recall information (p=0.04) and a trend toward statistical significance for greater improvement in word-finding (p=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance.
CONCLUSION: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.
METHODS: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment.
RESULTS: There was a greater improvement in the ability to recall information (p=0.04) and a trend toward statistical significance for greater improvement in word-finding (p=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance.
CONCLUSION: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.